You just read:

Rigel Announces Oral Presentation of TAVALISSE™ (fostamatinib disodium) Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress

News provided by

Rigel Pharmaceuticals, Inc.

Jun 22, 2017, 16:05 ET